Skip to main content
. 2022 Sep 23;13:1012552. doi: 10.3389/fphar.2022.1012552

FIGURE 3.

FIGURE 3

Mechanism of anti-PD-L1 therapy. After interferon exposure, tumor cells reactively express PD-L1, which binds to PD-1 on the surface of T cells and inhibits T cells. Anti-PD-1 or anti-PD-L1 antibodies can block the interaction of PD-1 with PD-L1 and reverse the inhibition of CD8+ T cells, thereby enhancing anti-tumor activity.